Literature DB >> 20716403

[Expression of DLL4 and VEGF in Lung Adenocarcinoma and their Relationship with Angiogenesis in Tumor.].

Xiaoping Li1, Qingfu Zhang, Bin Lu, Xueshan Qiu, Yang Luo, Weidong Zhang, Shun Xu.   

Abstract

BACKGROUND: Angiogenesis depends on the interaction of a variety of promoting factors and inhibiting factors. Vascular endothelial growth factor (VEGF) and Notch signaling pathway take part in this process. This experiment investigates the expression of Notch ligand DLL4 and VEGF in lung adenocarcinoma and their relationship with angiogenesis in tumor.
METHODS: Immunohistochemical method was used to detect DLL4, VEGF and CD34 protein expression in 80 cases of lung adenocarcinoma (including bronchioloalveolar carcinoma and common lung adenocarcinoma) paraffin section tissues.
RESULTS: The expression of DLL4 and VEGF was closely related to tumor diameter, clinical stage, histological grade and lymph node metastasis, the VEGF expression rate in DLL4 positive expression cases was significantly more than the DLL4 negative cases, the correlation between microvascular density and DLL4, VEGF co-expression was more significant, the expression of DLL4 in common lung adenocarcinoma was significantly higher than that in bronchioloalveolar carcinoma.
CONCLUSIONS: The prognosis of lung adenocarcinoma is significant correlated with the angiogenesis, high expression of DLL4 is closely related to the metastasis and the prognosis.

Entities:  

Year:  2009        PMID: 20716403     DOI: 10.3779/j.issn.1009-3419.2009.02.04

Source DB:  PubMed          Journal:  Zhongguo Fei Ai Za Zhi        ISSN: 1009-3419


  2 in total

Review 1.  The Role of DLLs in Cancer: A Novel Therapeutic Target.

Authors:  Meng-Xi Xiu; Yuan-Meng Liu; Bo-Hai Kuang
Journal:  Onco Targets Ther       Date:  2020-05-07       Impact factor: 4.147

Review 2.  EphrinB2-EphB4 Signaling in Neurooncological Disease.

Authors:  Andras Piffko; Christian Uhl; Peter Vajkoczy; Marcus Czabanka; Thomas Broggini
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.